Breaking News, Collaborations & Alliances

Tiziana Enters Manufacturing Tie-up with STC Biologics

For GMP manufacturing of an anti-interleukin-6-receptor monoclonal antibody for clinical studies in patients with COVID-19.

By: Contract Pharma

Contract Pharma Staff

Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, has entered an agreement with STC Biologics for GMP manufacturing of TZLS-501, an anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (mAb) acquired from Novimmune in 2017, currently in agreement with Bristol Myers Squibb (BMS).   Tiziana is simultaneously developing an inhalation technology, in collaboration with Sciarra Laboratories, for the direct delivery of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters